DISCLAIMER: The Tatum Report does not provide any medical advice. Information found in this article is based on claims from multiple sources. Please do your due diligence when it comes to your personal medical care.
According to Forbes, Pfizer revealed it is testing a pill, “an oral antiviral drug,” that would prevent contracting the CCP virus after being exposed to the virus. In a press release, “the company announced Monday, as scientists around the world work to develop new tools to fight Covid-19 and ease the burden on overwhelmed hospitals.”
It’s clear now, the “vaccines” do not prevent infection but can make the disease less virulent once a person is infected. These so-called “breakthrough cases” have flummoxed the American public’s understanding of and perhaps trust in the vaccines. A medication that would actually prevent contracting the disease would calm fraying nerves.
In its press release, Pfizer stated, “The start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel oral antiviral candidate PF-07321332, co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection. This Phase 2/3 trial is… is enrolling individuals who are at least 18 years old and live in the same household as an individual with a confirmed symptomatic SARS-CoV-2 infection.”
The study will include 2,660 adults who are healthy and residing with an infected person who has confirmed symptoms of the disease. Pfizer will “test whether the antiviral drug… can prevent Covid-19 infection….”
Pfizer also said the efficacy and safety of the antiviral taken with ritonavir, “another antiviral widely used to treat HIV.” They will administer the combination to two-thirds of the trial participants twice a day for five or ten days. They will give the remaining third of the trial patients a placebo. Early-stage results indicated the antiviral combination “was safe and well tolerated.”
Forbes noted, “Dr. Mikael Dolsten, chief scientific officer of Pfizer’s research and development division, said tackling the virus will need treatments that complement vaccines. Dolsten said such a therapy could ‘stop the virus early… potentially preventing symptomatic disease in those who have been exposed and inhibiting the onset of infection in others.’”
In addition, Pfizer is exploring whether they could also use the drug combination as a treatment once someone is infected. Forbes reported that Merck and Ridgeback Biotherapeutics are also testing a pill to treat the CCP virus. They expect to have late-stage clinical trials data on molnupiravir by year’s end.
Forbes also notes other “oral and nasal Covid-19 vaccines…” are being developed. If successful, they believe this could reduce needle anxiety and worry over blood-borne pathogens. These products would be more easily stored and transported, not requiring the “ultracold temperatures…” needed to preserve Pfizer and Moderna injections. Forbes also believes the oral and nasal delivery methods would help “eliminate many of the barriers hindering widespread immunization around the world.”
- Alaska Couple Speaks Out Over FBI Harassment Concerning January 6 - January 4, 2022
- One Cop Murdered, A Second Seriously Wounded Responding to Barking Dogs Complaint - December 31, 2021
- Parents Accuse L.A. School District of Using Dirty Tricks to Get Kids “Vaccinated” - December 31, 2021